KdT Ventures reposted this
ELEGEN today announces its first partnership with GSK- $35M to start with more to come. Cell-free, clonal, scaled (1G+)DNA manufactured in 7 days or less is the only way we enable personalized genetic medicine- and I can confidently say only ELEGEN can do this. The recent Moderna Lancet publication on their Phase II personalized Melanoma Vaccine (20 unique antigens per patient)last week said it best: "Logistical complexity is intrinsic to personalized neoepitope selection and manufacture...future development must continue to optimize methods to facilitate timely manufacturing." Sure we all know that timely manufacturing is key, but get this. The paper also mentioned in the discussion that the " delayed separation <of the two trial arms> might be partly attributable to the manufacturing time of mRNA-4157". ELEGEN will save time, money, and lives. Best kind of investment. Only frustrating part is seeing so many inferior technologies get gobs of funding based on hype. Customers see the power here, and GSK will be the first of many. #personalizedmedicine #dna #mrna #mrnavaccines
We’re thrilled to announce our collaboration with GSK to provide a fast, turnkey supply of long, accurate, high-complexity ENFINIA DNA for the development of GSK's vaccines and medicines! Read the full press release: https://bit.ly/3OCwC2b #longDNA #EnfiniaDNA #biotech #mRNAvaccines #SyntheticDNA #cellfree
Thank you Cain!
Innovator & Entrepreneur in Biotechnology
9moBravo Cain, everyone at HDT Bio is very impressed by the ELEGEN team and technology. Excited to see where it goes from here.